Form 4: Lyell CSO Sells Shares for Tax Obligations

Lyell Immunopharma's Chief Scientific Officer, Gary K. Lee, sold shares to cover tax withholding obligations from vested restricted stock units.

Summary

• Chief Scientific Officer Gary K. Lee of Lyell Immunopharma, Inc. reported two sales of common stock.
• On August 11, 2025, 131 shares were sold at a weighted average price of $10.526 per share, with prices ranging from $10.045 to $11.00.
• On August 12, 2025, an additional 136 shares were sold at a weighted average price of $10.338 per share, with prices ranging from $10.120 to $10.415.
• Both sales were automatic transactions to cover tax withholding obligations arising from the settlement of vested restricted stock units.
• Following these transactions, the reporting person beneficially owns 8,957 shares.
• The reported share amounts reflect a 1-for-20 reverse stock split effected by the Issuer on May 30, 2025.
• The reporting person also acquired 390 shares on May 18, 2025, under the Issuer's 2021 Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The filing reports routine insider sales for tax purposes, which are neutral to slightly positive as they indicate RSU vesting. The officer also acquired shares via ESPP. The reverse stock split is noted but its impact isn't detailed here.

Positives

• The sales were for tax withholding, indicating the vesting of restricted stock units, which is a positive event for the employee.
• The reporting person acquired 390 shares under the Employee Stock Purchase Plan, indicating continued participation and potential confidence in the company.

Negatives

• Reduction in direct beneficial ownership by a key officer, although for a non-discretionary reason.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction for tax purposes, common across all industries when restricted stock units vest. It does not provide specific insights into Lyell Immunopharma's industry position or trends beyond the fact that it issues equity compensation.

Comparison to Industry Standards

• The practice of selling shares to cover tax withholding obligations upon RSU vesting is standard across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where equity compensation is prevalent.
• The 1-for-20 reverse stock split on May 30, 2025, is a corporate action often undertaken by companies, including those in the biotech industry, to increase share price, meet listing requirements, or improve market perception.

Related Party Transactions

• The reported sales by Chief Scientific Officer Gary K. Lee are considered related party transactions as they involve an executive officer of the company.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting (already accounted for), but the sales themselves are routine and unlikely to significantly impact share price unless they were discretionary and large. The reverse stock split impacts share count and price per share, but not overall value.
• Employees: The vesting of RSUs and participation in the ESPG indicate standard employee equity compensation practices are in place.

Key Dates

Recommendation

This Form 4 filing details routine insider sales by a Chief Scientific Officer to cover tax obligations from vested restricted stock units. Such transactions are common and generally not indicative of a change in management's long-term view of the company. The officer also acquired shares through an employee stock purchase plan, suggesting continued participation. While the sales reduce direct beneficial ownership, they are not discretionary and therefore do not signal a negative outlook. The filing itself does not provide sufficient information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate, pending further fundamental analysis of Lyell Immunopharma.

Keywords

Lyell Immunopharma, LYEL, SEC Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Chief Scientific Officer, Gary K. Lee, Reverse Stock Split, Employee Stock Purchase Plan